Filtered By:
Source: Cardiology Journal
This page shows you your search results in order of date. This is page number 12.
Order by Relevance | Date
Total 265 results found since Jan 2013.
Transcatheter aortic valve implantation results are not superimposable to surgery in patients with aortic stenosis at low surgical risk
CONCLUSIONS: TAVI and SVAR in the treatment of AS in the patients at low surgical risk are not superimposable. In particular, if 30-day and 1-year mortality, major bleeding and acute kidney injury were significantly lower for TAVI, the need of new PM implantation and paravalvular leak were significantly lower in SAVR. Consequently, we suggest the need of more trials to evaluate the effectiveness of TAVI as routine therapeutic procedure in the treatment of patients with low surgical risk AS.PMID:34622437 | DOI:10.5603/CJ.a2021.0114
Source: Cardiology Journal - October 8, 2021 Category: Cardiology Authors: Maria Cristina Acconcia Marco Alfonso Perrone Domenico Sergi Marco Di Luozzo Massimo Marchei Pasquale De Vico Antonio Sili Scavalli Giuseppe Pannarale Marcello Chiocchi Carlo Gaudio Francesco Romeo Quintilio Caretta Francesco Barill à Source Type: research
Efficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials
CONCLUSIONS: Alirocumab and evolocumab could ameliorate lipid profile and reduce the risk of cardiac disorders and stroke with satisfactory safety and tolerability. However, injection-site reactions should be paid attention to.PMID:34581425 | DOI:10.5603/CJ.a2021.0110
Source: Cardiology Journal - September 28, 2021 Category: Cardiology Authors: Qiang Geng Xuan Li Qingjiao Sun Zhengzhong Wang Source Type: research
The efficacy and safety of quantitative flow ratio-guided complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease: A pilot randomized controlled trial
CONCLUSIONS: In conclusion, STEMI and MVD patients can benefit from QFR-G-CR of non-IRA lesions in the initial stages of acute MI. This can help reduce incidences of major adverse cardiovascular events and unstable angina, relative to IRA treatment only. Chinese Clinical Trial Registration number: ChiCTR2100044120.PMID:34581424 | DOI:10.5603/CJ.a2021.0111
Source: Cardiology Journal - September 28, 2021 Category: Cardiology Authors: Jing Zhang Mingyan Yao Xinwei Jia Huiping Feng Jingjing Fu Wei Tang Hongliang Cong Source Type: research
Efficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials
CONCLUSIONS: Alirocumab and evolocumab could ameliorate lipid profile and reduce the risk of cardiac disorders and stroke with satisfactory safety and tolerability. However, injection-site reactions should be paid attention to.PMID:34581425 | DOI:10.5603/CJ.a2021.0110
Source: Cardiology Journal - September 28, 2021 Category: Cardiology Authors: Qiang Geng Xuan Li Qingjiao Sun Zhengzhong Wang Source Type: research
The efficacy and safety of quantitative flow ratio-guided complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease: A pilot randomized controlled trial
CONCLUSIONS: In conclusion, STEMI and MVD patients can benefit from QFR-G-CR of non-IRA lesions in the initial stages of acute MI. This can help reduce incidences of major adverse cardiovascular events and unstable angina, relative to IRA treatment only. Chinese Clinical Trial Registration number: ChiCTR2100044120.PMID:34581424 | DOI:10.5603/CJ.a2021.0111
Source: Cardiology Journal - September 28, 2021 Category: Cardiology Authors: Jing Zhang Mingyan Yao Xinwei Jia Huiping Feng Jingjing Fu Wei Tang Hongliang Cong Source Type: research
Efficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials
CONCLUSIONS: Alirocumab and evolocumab could ameliorate lipid profile and reduce the risk of cardiac disorders and stroke with satisfactory safety and tolerability. However, injection-site reactions should be paid attention to.PMID:34581425 | DOI:10.5603/CJ.a2021.0110
Source: Cardiology Journal - September 28, 2021 Category: Cardiology Authors: Qiang Geng Xuan Li Qingjiao Sun Zhengzhong Wang Source Type: research
The efficacy and safety of quantitative flow ratio-guided complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease: A pilot randomized controlled trial
CONCLUSIONS: In conclusion, STEMI and MVD patients can benefit from QFR-G-CR of non-IRA lesions in the initial stages of acute MI. This can help reduce incidences of major adverse cardiovascular events and unstable angina, relative to IRA treatment only. Chinese Clinical Trial Registration number: ChiCTR2100044120.PMID:34581424 | DOI:10.5603/CJ.a2021.0111
Source: Cardiology Journal - September 28, 2021 Category: Cardiology Authors: Jing Zhang Mingyan Yao Xinwei Jia Huiping Feng Jingjing Fu Wei Tang Hongliang Cong Source Type: research
Efficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials
CONCLUSIONS: Alirocumab and evolocumab could ameliorate lipid profile and reduce the risk of cardiac disorders and stroke with satisfactory safety and tolerability. However, injection-site reactions should be paid attention to.PMID:34581425 | DOI:10.5603/CJ.a2021.0110
Source: Cardiology Journal - September 28, 2021 Category: Cardiology Authors: Qiang Geng Xuan Li Qingjiao Sun Zhengzhong Wang Source Type: research
The efficacy and safety of quantitative flow ratio-guided complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease: A pilot randomized controlled trial
CONCLUSIONS: In conclusion, STEMI and MVD patients can benefit from QFR-G-CR of non-IRA lesions in the initial stages of acute MI. This can help reduce incidences of major adverse cardiovascular events and unstable angina, relative to IRA treatment only. Chinese Clinical Trial Registration number: ChiCTR2100044120.PMID:34581424 | DOI:10.5603/CJ.a2021.0111
Source: Cardiology Journal - September 28, 2021 Category: Cardiology Authors: Jing Zhang Mingyan Yao Xinwei Jia Huiping Feng Jingjing Fu Wei Tang Hongliang Cong Source Type: research
Efficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials
CONCLUSIONS: Alirocumab and evolocumab could ameliorate lipid profile and reduce the risk of cardiac disorders and stroke with satisfactory safety and tolerability. However, injection-site reactions should be paid attention to.PMID:34581425 | DOI:10.5603/CJ.a2021.0110
Source: Cardiology Journal - September 28, 2021 Category: Cardiology Authors: Qiang Geng Xuan Li Qingjiao Sun Zhengzhong Wang Source Type: research
The efficacy and safety of quantitative flow ratio-guided complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease: A pilot randomized controlled trial
CONCLUSIONS: In conclusion, STEMI and MVD patients can benefit from QFR-G-CR of non-IRA lesions in the initial stages of acute MI. This can help reduce incidences of major adverse cardiovascular events and unstable angina, relative to IRA treatment only. Chinese Clinical Trial Registration number: ChiCTR2100044120.PMID:34581424 | DOI:10.5603/CJ.a2021.0111
Source: Cardiology Journal - September 28, 2021 Category: Cardiology Authors: Jing Zhang Mingyan Yao Xinwei Jia Huiping Feng Jingjing Fu Wei Tang Hongliang Cong Source Type: research
Efficacy and safety of PCSK9 inhibition in cardiovascular disease: a meta-analysis of 45 randomized controlled trials
CONCLUSIONS: Alirocumab and evolocumab could ameliorate lipid profile and reduce the risk of cardiac disorders and stroke with satisfactory safety and tolerability. However, injection-site reactions should be paid attention to.PMID:34581425 | DOI:10.5603/CJ.a2021.0110
Source: Cardiology Journal - September 28, 2021 Category: Cardiology Authors: Qiang Geng Xuan Li Qingjiao Sun Zhengzhong Wang Source Type: research
The efficacy and safety of quantitative flow ratio-guided complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease: A pilot randomized controlled trial
CONCLUSIONS: In conclusion, STEMI and MVD patients can benefit from QFR-G-CR of non-IRA lesions in the initial stages of acute MI. This can help reduce incidences of major adverse cardiovascular events and unstable angina, relative to IRA treatment only. Chinese Clinical Trial Registration number: ChiCTR2100044120.PMID:34581424 | DOI:10.5603/CJ.a2021.0111
Source: Cardiology Journal - September 28, 2021 Category: Cardiology Authors: Jing Zhang Mingyan Yao Xinwei Jia Huiping Feng Jingjing Fu Wei Tang Hongliang Cong Source Type: research
